Advances in Monoclonal Antibodies in Cancer Treatment
Author Information
Author(s): P.N. Goodfellow, G. Banting, P.W. Andrews, A. Munro Neville, K.D. Bagshawe, W.J. Gullick, E.S. Lennox, D. Catovsky, J.-P. Mach, E. Matutes, H. Feichtinger, H.B. Coakham, K. Blaser, A. Ranki, E.J. Nouwen, K. Krohn, R. Arndt, Z. Rudolf, K. Bosslet, J.Y. Douillard, H. Haisma, S. Ferrone, K.A. Chester, R.H.J. Begent, K.E. Britton, D.S. Fairweather, A.A. Epenetos, D.H. Carr, R.P. Beaney, P.O. Schnell, G. Paganelli, N. Pateisky, B. Foxwell, J.M. Goldman, A. Frankel, G. Laurent, E.M. Rankin, P.J.A. Capel, C.H. Poynton, M. Clark, R.G. Fairchild, S. Canevari
Primary Institution: University of London, Royal Postgraduate Medical School
Conclusion
Monoclonal antibodies (McAbs) have shown promise in improving the detection and treatment of various cancers.
Supporting Evidence
- Monoclonal antibodies can differentiate between normal and cancerous cells.
- Studies show that monoclonal antibodies can improve cancer detection rates.
- Monoclonal antibodies have been used to target specific cancer markers.
- Research indicates that monoclonal antibodies can enhance treatment efficacy.
- Immunoassays using monoclonal antibodies have shown high specificity for cancer antigens.
- Monoclonal antibodies have been effective in identifying various tumor types.
- Clinical trials have demonstrated the potential of monoclonal antibodies in cancer therapy.
- Monoclonal antibodies can be used in combination with other treatments for better outcomes.
Takeaway
Scientists are using special proteins called monoclonal antibodies to help find and treat cancer better.
Methodology
Various studies were conducted using monoclonal antibodies to analyze cancer cells and their characteristics.
Limitations
The studies often had small sample sizes and varied methodologies.
Want to read the original?
Access the complete publication on the publisher's website